Gilead Sciences, Inc. GILD

Overview

Gilead Sciences, Inc. is a frontline biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company's mission revolves around addressing unmet medical needs across the United States, Europe, and other international markets. Since its inception in 1987, Gilead Sciences has been committed to pushing the boundaries of scientific research to create therapeutic solutions that can significantly improve the quality of life for patients worldwide. With its headquarters in Foster City, California, Gilead stands as a pioneer in the field, forming strategic collaboration agreements with various entities including Arcus Biosciences, Inc., Merck Sharp & Dohme Corp., and many others to bolster its research and development efforts. The company's extensive portfolio underscores its dedication to combating some of today's most challenging diseases, including HIV/AIDS, COVID-19, viral hepatitis, and certain oncological disorders.

Products and Services

• HIV/AIDS treatment:

Gilead provides a robust lineup of products for HIV/AIDS management, including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla. Each of these treatments plays a vital role in suppressing the virus, improving patient health, and reducing the risk of HIV transmission.

• COVID-19:

Veklury (Remdesivir) serves as an injection for intravenous use designed to treat COVID-19. It represents one of the first antiviral treatments to receive emergency use authorization for addressing the global pandemic, demonstrating efficacy in helping hospitalized patients recover faster.

• Viral Hepatitis:

Gilead offers Epclusa, Harvoni, Vemlidy, and Viread for the treatment of hepatitis B and C, contributing to the global effort to manage and potentially eliminate viral hepatitis as a major public health threat.

• Oncology:

The company has made significant strides in cancer treatment with its products Yescarta, Tecartus, and Trodelvy, focusing on innovative therapies that can potentially transform the treatment landscape for patients suffering from various cancers.

• Pulmonary Arterial Hypertension:

Letairis is an oral medication developed for the treatment of pulmonary arterial hypertension (PAH), aiming to improve exercise ability and delay clinical worsening in patients.

• Severe Fungal Infections:

AmBisome, a liposomal formulation, is targeted at treating serious invasive fungal infections, offering a critical solution for immunocompromised patients such as those undergoing chemotherapy or with HIV/AIDS.

Across these diverse therapeutic areas, Gilead Sciences maintains a steadfast commitment to innovation, safety, and efficacy, striving to fulfill its mission of advancing healthcare and enhancing patient outcomes around the globe.